Predictors of consent to pharmacogenomics testing in the IDEAL study

Alison B. Jazwinski, Paul J. Clark, Alexander J. Thompson, Stuart C. Gordon, Eric J. Lawitz, Stephanie Noviello, Clifford A. Brass, Lisa D. Pedicone, Janice K. Albrecht, Mark Sulkowski, Andrew J. Muir

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. OBJECTIVE: To characterize the groups of patients who accepted or declined pharmacogenomic testing in the IDEAL study. METHODS: Clinical and demographic factors and treatment outcomes were compared at all sites that had approved pharmacogenomic testing. Differences between patients who consented to and declined pharmacogenomic testing were analyzed using Student's t-test and χ2-test. RESULTS: In total, 109 of 118 sites participated in the pharmacogenomic substudy, and 1674 of 2949 (57%) patients enrolled at these sites consented to pharmacogenomic testing. More patients treated in academic medical centers than in community centers (60 vs. 52%, P

Original languageEnglish (US)
Pages (from-to)619-623
Number of pages5
JournalPharmacogenetics and Genomics
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 2013

    Fingerprint

Keywords

  • Hepatitis C
  • Peginterferon
  • Pharmacogenomics
  • Ribavirin

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Jazwinski, A. B., Clark, P. J., Thompson, A. J., Gordon, S. C., Lawitz, E. J., Noviello, S., ... Muir, A. J. (2013). Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenetics and Genomics, 23(11), 619-623. https://doi.org/10.1097/FPC.0000000000000002